Cybin Inc Cash Flow Conversion Efficiency
Cybin Inc cash flow conversion efficiency. Based on the latest financial reports, Cybin Inc (CYBN) has a cash flow conversion efficiency ratio of -0.117x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-31.95 Million ≈ $-23.11 Million USD) by net assets (CA$273.93 Million ≈ $198.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cybin Inc (2020–2025)
Cash flow conversion efficiency of Cybin Inc from 2020 to 2025. This chart illustrates how Cybin Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CYBN stock price for real-time trading data and today's change.
Cybin Inc Cash Flow Conversion Ratio Explained
Cybin Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cybin Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cybin Inc ranked by their cash flow conversion efficiency. Also see Cybin Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Xinning Modern Logist
SHE:300013
|
0.215x |
|
Itafos Corp
V:IFOS
|
0.003x |
|
Zhengzhou Tiamaes Technology Co Ltd
SHE:300807
|
0.023x |
|
NHN KCP Corp
KQ:060250
|
0.513x |
|
Zhejiang Hengwei Battery Co. Ltd.
SHE:301222
|
N/A |
|
Seaport Entertainment Group Inc.
NYSE:SEG
|
-0.028x |
|
Materialise NV
F:06MA
|
0.041x |
|
Cohen Circle Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CCIR
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Cybin Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Cybin Inc from 2020 to 2025. Review CYBN free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | CA$237.20 Million ≈ $171.59 Million |
CA$-101.30 Million ≈ $-73.28 Million |
-0.427x | -80.93% |
| 2024-03-31 | CA$291.93 Million ≈ $211.18 Million |
CA$-68.91 Million ≈ $-49.85 Million |
-0.236x | +76.00% |
| 2023-03-31 | CA$48.23 Million ≈ $34.89 Million |
CA$-47.43 Million ≈ $-34.31 Million |
-0.983x | -65.65% |
| 2022-03-31 | CA$76.16 Million ≈ $55.09 Million |
CA$-45.21 Million ≈ $-32.70 Million |
-0.594x | -168.68% |
| 2021-03-31 | CA$86.12 Million ≈ $62.30 Million |
CA$-19.03 Million ≈ $-13.76 Million |
-0.221x | +76.90% |
| 2020-03-31 | CA$1.45 Million ≈ $1.05 Million |
CA$-1.38 Million ≈ $-1.00 Million |
-0.956x | -- |
About Cybin Inc
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anx… Read more